Sign In
Buy IGI
$15.67
+0 (+0%)
At Close: Jul 31, 2026
IGI's Financial Strength Rating Upgraded to “A” (Strong)/Stable by S&P Global Ratings
04:10pm, Tuesday, 28'th Oct 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that rating agency S&P Global Ratings (“S&P”) has
IGI Appoints Malcolm Barnes as Head of Specialty Treaty
09:15am, Monday, 27'th Oct 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that London market professional Malcolm Barnes has joi
Western Asset Investment Grade Opportunity Trust Inc. Announces Financial Position as of August 31, 2025
08:00am, Monday, 27'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Category: Financials.
IGI to Release Third Quarter and Nine Month 2025 Financial Results on November 4, 2025
09:00am, Wednesday, 08'th Oct 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that it expects to release financial results for the t
Western Asset Investment Grade Opportunity Trust Inc. (NYSE: IGI) Announces Portfolio Management Team Update
08:00am, Tuesday, 19'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Category: Fund Announcement.
IGI Announces Quarterly Ordinary Common Share Dividend
04:05pm, Thursday, 14'th Aug 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that its Board of Directors has declared an ordinary c
IGI Reports Second Quarter and Half Year 2025 Unaudited Financial Results
04:10pm, Tuesday, 05'th Aug 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the second quarter and first six
India's Glenmark Pharma unit, Abbvie sign exclusive licensing pact
07:44am, Thursday, 10'th Jul 2025
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK , July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and
IGI to Release Second Quarter and Half Year 2025 Financial Results on August 5, 2025
09:00am, Wednesday, 09'th Jul 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that it expects to release financial results for the s
IGI Announces Increase in Quarterly Ordinary Common Share Dividend
04:05pm, Thursday, 15'th May 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that its Board of Directors has voted to increase the
IGI Reports First Quarter of 2025 Unaudited Financial Results
04:05pm, Tuesday, 06'th May 2025
HAMILTON, Bermuda--(BUSINESS WIRE)--International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the first quarter of 2025. Highli
Western Asset Investment Grade Opportunity Trust Inc. Announces Results of Annual Meeting of Stockholders
08:00am, Thursday, 17'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Category: Fund Announcement.
Western Asset Investment Grade Opportunity Trust Inc. Announces Financial Position as of February 28, 2025
08:00am, Wednesday, 16'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Category: Financials.
